Quantum-Synaptic Immunotherapy Mapping Using Low-Frequency Electromagnetic Resonance and Machine ā¦ (NCT07221565) | Clinical Trial Compass
By InvitationPhase 1/2
Quantum-Synaptic Immunotherapy Mapping Using Low-Frequency Electromagnetic Resonance and Machine Learning-Based Cytokine Forecasting
United States120 participantsStarted 2025-10-23
Plain-language summary
The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with each other. The goal is to see if this "quantum-synaptic" signaling effect can help stabilize immune activity and reduce the number of autoimmune flare-ups in people living with conditions such as lupus, rheumatoid arthritis, or multiple sclerosis.
Participants will receive either an active or a sham (placebo) LF-EMR session three times per week for twelve weeks. Each session is completely non-invasive. Blood samples will be collected to study cytokines (immune-system messenger molecules), gene-expression patterns, and electrical field coherence among immune cells.
A machine-learning system will analyze these data to predict inflammation patterns and guide individualized treatment settings. All participant data will be securely recorded and time-stamped to ensure transparency and privacy.
The expected outcome of the study is a measurable reduction in autoimmune flare frequency and symptom severity, along with improved understanding of how electromagnetic signaling might safely regulate immune function.
Who can participate
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. Male or female participants aged 18-70 years.
ā. Clinical diagnosis of a systemic autoimmune disorder (e.g., systemic lupus erythematosus, rheumatoid arthritis, or multiple sclerosis) confirmed for at least 12 months.
ā. Stable disease-modifying therapy or corticosteroid regimen for at least 8 weeks prior to enrollment.
ā. Willingness to maintain current medication schedule for the duration of the study.
ā. Ability to provide written informed consent and comply with study procedures.
ā. Access to stable internet or smartphone connection for digital consent verification and symptom tracking.
Exclusion criteria
ā. Presence of an implanted medical or electronic device (e.g., pacemaker, defibrillator, deep brain stimulator).
ā. Pregnancy or lactation.
ā. Active infection, malignancy, or significant hepatic, renal, or cardiovascular disease.
ā. Known photosensitivity, seizure disorder, or history of uncontrolled epilepsy.